Last updated: 2026-09-27 02:25:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Celcuity Inc. (CELC) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $79.56, with a market capitalisation of $3.88B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $44.42 to $151.02. This page covers its latest market performance, valuation, price trends and company information.
$3.88B | |
$80.00 | |
$151.02 | |
$4.03 | |
$79.37 | |
445.21K | |
1.15M | |
-- | |
$151.02 | |
$44.42 | |
-- | |
-- |
Celcuity Inc. (CELC) last closed at $79.37 as of 2026-09-25 23:31:00, unchanged from the previous close of $79.37.
During the latest regular trading session, CELC traded between $4.03 and $151.02, with a volume of 445.21K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Celcuity Inc. (CELC) moved from $84.91 to $79.56, representing a decline of 6.31% ($5.35).
The stock traded between $77.07 and $87.50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 855.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33.0%
CELC is currently trading at $79.56, placing it 33.0% of the way from its 52-week low of $44.42 to its 52-week high of $151.02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Celcuity Inc. (CELC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.